-
Clinicians now have a second option in treating trichomoniasis, which accounts for nearly one-third of the 15.4 million cases of sexually transmitted diseases (STDs) in the United States. The Food and Drug Administration (FDA) has approved Tindamax (tinidazole) for the treatment of trichomoniasis, giardiasis, intestinal amebiasis, and amebic liver abscess.
-
The 18-year-old patient before you, scheduled for an annual exam, is sexually active and admits that condoms are not always used. What is your next move? If the patient is female, chances are she will be tested for chlamydia, but if the patient is male and asymptomatic, your practice may not include a routine screen for the sexually transmitted disease (STD). New research may have you rethink your approach.
-
Get ready for wider availability of the OraQuick HIV-1/2 rapid HIV test: with a June 2004 waiver issued by the Food and Drug Administration (FDA), the test now can be used by more than 180,000 sites in the United States, including outreach clinics, community-based organizations, and physicians offices.
-
Want to drive more men toward your family planning clinic? You may want to consider adding clinic-based vasectomies. The Womens Health Care Clinic at Harbor-University of California Los Angeles (UCLA) Medical Center in Torrance has found success in steering its program in this direction.
-
Since the extended regimen pill Seasonale (Barr Laboratories, Pomona, NY) hit pharmacy shelves in October 2003, it has become the fourth most-prescribed oral contraceptive in the United States. What do you need to know in counseling women about this new option?
-
The British government will soon allow over-the-counter sales of Mercks simvastatin (Zocor), marking the first time any country has allowed the OTC sale of a statin.
-
-
The pre-discharge initiation of beta blocker therapy for decompensated heart failure patients increased the number of patients on beta blockers at 60 days without an increase in length of stay or adverse effects.
-
Data showed a strong trend toward benefit with ICD therapy in patients with nonischemic cardiomyopathy.
-
CPR values as a continuous variable have independent predictive value for subsequent coronary events in apparently healthy women.
